Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8927225 | 0.97 | LMNA (0.42) | DNM1LMNAFDPSTSHRTHRB | |
| SCHEMBL6870580 | 0.92 | DNM1 (0.39) | DNM1LMNAFDPSTSHRTHRB | |
| SCHEMBL8927188 | 0.87 | DNM1 (0.36) | DNM1LMNAFDPSTSHRCA2 | |
| SCHEMBL3793387 | 0.79 | DNM1 (0.50) | DNM1LMNAFDPSTSHRTHRB | |
| SCHEMBL1931301 | 0.79 | DNM1 (0.50) | DNM1LMNAFDPSTSHRTHRB | |
| SCHEMBL8840359 | 0.79 | DNM1 (0.50) | DNM1LMNAFDPSTSHRTHRB | |
| SCHEMBL6754668 | 0.79 | DNM1 (0.50) | DNM1LMNAFDPSTSHRTHRB | |
| SCHEMBL1400123 | 0.79 | DNM1 (0.50) | DNM1LMNAFDPSTSHRTHRB | |
| SCHEMBL21175601 | 0.79 | DNM1 (0.50) | DNM1LMNAFDPSTSHRTHRB | |
| SCHEMBL8006167 | 0.79 | DNM1 (0.50) | DNM1LMNAFDPSTSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002313-A1 | [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2024-01-04 | — | — | US | disclosed |
| CN-117098749-A | [11C] Labeled acyclic retinoids, central nervous system activators and methods for their manufacture | 国立研究开发法人国立长寿医疗研究中心 | 2023-11-21 | — | — | CN | disclosed |
| EP-4249058-A1 | [11C]-LABELLED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | National Center for Geriatrics and Gerontology (JP) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022107865-A1 | [11C]-LABELLED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | 国立研究開発法人国立長寿医療研究センター | 2022-05-27 | — | — | WO | disclosed |
| US-11274248-B2 | Lanthanoid-containing inorganic material microparticles, wavelength-converting ink, coated article, and determination apparatus | SEKISUI CHEMICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210054271-A1 | LANTHANOID-CONTAINING INORGANIC MATERIAL MICROPARTICLES, WAVELENGTH-CONVERTING INK, COATED ARTICLE, AND DETERMINATION APPARATUS | SEKISUI CHEMICAL CO., LTD. (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3409748-B1 | LANTHANOID-CONTAINING INORGANIC MATERIAL MICROPARTICLES, WAVELENGTH-CONVERTING INK, COATED ARTICLE, AND DETERMINATION APPARATUS | SEKISUI CHEMICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| EP-3409748-A1 | LANTHANOID-CONTAINING INORGANIC MATERIAL MICROPARTICLES, WAVELENGTH-CONVERTING INK, COATED ARTICLE, AND DETERMINATION APPARATUS | Sekisui Chemical Co., Ltd. (JP) | 2018-12-05 | — | — | EP | disclosed |
| US-5600034-A | HEAT TREATING DIALLYL ETHERS IN PRESENCE OF CATALYST CONTAINING PALLADIUM AND PHOSPHORUS COMPOUNDS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-02-04 | — | — | US | disclosed |
| US-5583271-A | Method for continuously producing alkadienols | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002313-A1 | [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | NR2E3, FABP7, RARB | DNM1 3275/4885LMNA 4543/4885FDPS 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.